Accelero Biostructures
About Accelero Biostructures
Posts by :
May 2019: Accelero Biostructures, Inc. has received additional non-dilutive funding from the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) Phase II program
San Francisco: May 2019
Accelero Biostructures, Inc., has received additional non-dilutive funding from the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) Phase II program. Accelero Bio has developed novel technologies and tools for accelerating structure-based drug discovery using its deep expertise in high-throughput protein X-ray crystallography.
“We are very excited to receive this additional highly competitive Phase II funding from NIH, which cements our R&D and business plans enabling us to advance our mission to drive early drug discovery to develop new medicines to help people around the world”, said Debanu Das, Co-Founder and CEO.
The funds will be used to complete development of the Accelero Biostructures ABS-OneStepTM platform to discover novel leads for developing new therapeutics. X-ray crystallography is the gold standard for determining the exact binding orientation of molecules, which is an essential step in this process.
Accelero Biostructures was formed in January 2015 with support from the University of California’s QB3 program and is now in its 5th year of operations. “We aim to dramatically increase the efficiency and reduce the cost of developing novel lead molecules for preclinical testing. Our platforms help in providing additional tools and technologies to the company’s customers and partners.”, said Ashley Deacon, Co-Founder and CSO.
Sept. 2016: Accelero Biostructures, Inc. has received non-dilutive funding from the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) Phase I program
San Francisco: September 2016
“Accelero Biostructures, Inc., has received non-dilutive funding from the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) program. Accelero Biostructures develops technologies and tools for accelerating structure-based drug discovery and protein engineering using its deep expertise in high-throughput protein X-ray crystallography.
“We are very excited to receive this highly competitive funding from NIH, which validates our R&D and business plans enabling us to progress on our mission to drive early drug discovery to eventually develop new products to help people around the world”, said Debanu Das, Co-Founder and CEO.
The funds will be used to develop parts of Accelero Bio’s platform to provide novel leads for developing new therapeutics. X-ray crystallography is the gold standard for determining the exact binding orientation of molecules, which is an essential step in this process. Leveraging the core team that was previously part of the high-throughput protein structure group of the NIH Protein Structure Initiative program at the Joint Center for Structural Genomics (JCSG) at Stanford Synchrotron Radiation Lightsource (SSRL), SLAC National Accelerator Laboratory (SLAC), Menlo Park, California, is key in the process, bringing on board approximately 40 years of combined team experience in the field. The developments will also benefit in several other applications in the field of protein x-ray crystallography.
Accelero Biostructures was formed in January 2015 with support from the University of California’s QB3 program and has been working with customers and partners for over a year. “We aim to dramatically increase the efficiency and reduce the cost of developing novel lead molecules for preclinical testing. Platform development will also help in providing additional tools and technologies to the company’s customers and partners.”, said Ashley Deacon, Co-Founder and CSO.
January 2015: Accelero Biostructures, Inc. is founded with help from the University of California’s QB3 program
San Francisco: January 2015
Accelero Biostructures, Inc. is founded with help from the University of California’s QB3 program